Posted by Michael Wonder on 03 Jun 2020
Law makers, government watchdog blast FDA for poor oversight of U.S. drug supply chain
2 June 2020 - A government watchdog blasted the FDA for fumbling its oversight of the safety of the U.S. drug supply chain, suggesting the agency is not adequately conducting drug safety inspections overseas.
The criticisms came in a Tuesday hearing before the Senate Finance Committee, at which a top official for the Government Accountability Office outlined a number of surprising deficiencies in the FDA’s surveillance of foreign drug manufacturing.
It highlighted, in particular, the agency’s longstanding practice of alerting drug makers in advance that it plans to conduct an inspection. U.S.-based drug makers do not get a similar heads-up.
